# US 2021/0330808 A1 · Small polymeric carriers for delivery of agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330808 A1
- Document ID: US20210330808A1
- Status: Published application
- Kind: A1
- Application number: 17/284,562
- Filed: 2019-10-11
- Published: 2021-10-28
- Earliest claimed: 2018-10-12
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Jingjing Sun; Song Li
- Web page: https://patentgrep.com/patent/US20210330808A1

## CPC

- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/12: Ketones
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 38/13: Cyclosporins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C08F 8/32: by reaction with amines
- C08F 212/30: {Sulfur}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS

## Abstract

A polymer includes a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one group including a plurality of hydroxyl groups, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one hydrophilic polymer.

## Claims

### Claim 1

A polymer, comprising: a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one group comprising a plurality of hydroxyl groups, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one hydrophilic polymer, wherein at least one of the first plurality of pendant groups or the second plurality of pendant groups is attached to the hydrophobic polymer backbone via a linking moiety comprising at least one group which is interactive via π-π stacking.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The polymer of claim 1 wherein the first plurality of pendant groups is attached to the hydrophobic polymeric backbone via a first linking group comprising at least a first group which is interactive via π-π stacking.

### Claim 5 (depends on 4)

The polymer of claim 4 wherein the at least a first group interactive via π-π stacking comprises an aromatic group.

### Claim 6 (depends on 5)

The polymer of claim 5 wherein the at least a first group interactive via π-π stacking comprises a benzyl group.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 4)

The polymer of claim 4 wherein the at least one group comprising a plurality of hydroxyl groups is a hydrophilic group.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 20)

The polymer of claim 20 wherein the nucleoside is selected from the group consisting of a gemcitabine, azacytidine, cytarabine, or a biologically active derivative thereof.

### Claim 20 (depends on 21)

The polymer of claim 21 wherein the therapeutic agent is a nucleoside.

### Claim 21 (depends on 10)

The polymer of claim 10 wherein the at least one group comprising a plurality of hydroxyl groups comprises a therapeutic agent or a diagnostic agent covalently attached to the first linking group via a moiety that is labile in vivo.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28 (depends on 21)

The polymer of claim 21 wherein a plurality of the polymers forms a micelle having a diameter no greater than 50 nm.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

A formulation, comprising: a plurality of polymers comprising a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one group comprising a plurality of hydroxyl groups, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one hydrophilic polymer, and at least a first compound which is a hydrophobic therapeutic compound or a hydrophobic diagnostic compound, wherein at least one of the first plurality of pendant groups or the second plurality of pendant groups is attached to the hydrophobic polymer backbone via a linking moiety comprising at least one group which is interactive via π-π stacking, and wherein the plurality of polymers self-assemble into nanocarriers in an aqueous environment into which the first compound is loaded.

### Claim 34 (depends on 33)

The formulation of claim 33 further comprising at least a second compound which is a therapeutic compound or a diagnostic compound and which is loaded into the nanocarriers.

### Claim 35

(canceled)

### Claim 36 (depends on 33)

The formulation of claim 33 wherein the first compound is a small molecule compound.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43 (depends on 33)

The formulation of claim 33 wherein the first compound is a chemotherapeutic compound, an antiviral compound, an antibiotic compound, an antimycotic compound, an anticancer compound, an anti-rejection compound, an analgesic compound, an antioxidant compound, an immunomodulating compound, or an anti-inflammatory compound.

### Claim 44 (depends on 43)

The formulation of claim 43 wherein the first compound is JP4-039, paclitaxel, docetaxel, FK506 (tacrolimus), cyclosporin A, a protoporphyrin, GW4064 (3-(2,6-Dichlorophenyl)-4-(3′-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole), rose bengal, epigallocatechin gallate, simvastatin, curcumin, indomethacin, JQ1, I-BET 151, I-BET 762, resiquimod, riluzole, tamoxifen, NLG-919 (an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor), sunitinib, imatinib, erlotinib, gefitinib, cetuximab, a c-Myc inhibitor such as 10058-F4 (5-[(4-ethylphenyl)methylene]-2-thioxo-4-thiazolidinone), cladribine, fludarabine, nelarabine, troxacitabine, capecitabine, 2′-fluoro-2′-deoxyadenosine, acyclovir, tenofovir, lamivudine, entecavir, GS-441524, GS-5734, 2′-C-methyladenosine, 7-deaza-2′-C-methyl-adenosine, 2′-C-methylguanosine, INX-08189, 2′-C-methylcytidine, 2′-C-methyluridine, 2′-C-ethynyladenosine, NITD008, NITD449, NITD203, 4′-C-azidocytidine, balapiravir, RO-9187, BCX4430, ribavirin, 6-azauridine, or 9-deazaadenosine.

### Claim 45

(canceled)

### Claim 46 (depends on 34)

The formulation of claim 34 wherein the second compound is a chemotherapeutic compound, an antiviral compound, an antibiotic compound, an antimycotic compound, an anticancer compound, an anti-rejection compound, an analgesic compound, an antioxidant compound, an immunomodulating compound, or an anti-inflammatory compound.

### Claim 47 (depends on 46)

The formulation of claim 46 wherein the second compound is a small molecule therapeutic compound.

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50 (depends on 46)

The formulation of claim 46 wherein the first compound and the second compound are independently selected from the group consisting of JP4-039, paclitaxel, docetaxel, FK506 (tacrolimus), cyclosporin A, a protoporphyrin, GW4064 (3-(2,6-Dichlorophenyl)-4-(3′-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole), rose bengal, epigallocatechin gallate, simvastatin, curcumin, indomethacin, JQ1, I-BET 151, I-BET 762, resiquimod, riluzole, tamoxifen, NLG-919 (an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor), sunitinib, imatinib, erlotinib, gefitinib, cetuximab, a c-Myc inhibitor such as 10058-F4(5-[(4-ethylphenyl)methylene]-2-thioxo-4-thiazolidinone), cladribine, fludarabine, nelarabine, troxacitabine, capecitabine, 2′-fluoro-2′-deoxyadenosine, acyclovir, tenofovir, lamivudine, entecavir, GS-441524, GS-5734, 2′-C-methyladenosine, 7-deaza-2′-C-methyl-adenosine, 2′-C-methylguanosine, INX-08189, 2′-C-methylcytidine, 2′-C-methyluridine, 2′-C-ethynyladenosine, NITD008, NITD449, NITD203, 4′-C-azidocytidine, balapiravir, RO-9187, BCX4430, ribavirin, 6-azauridine, and 9-deazaadenosine.

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54 (depends on 33)

The formulation of claim 33 wherein the first plurality of pendant groups is attached to the hydrophobic polymeric backbone via a first linking group comprising at least a first group which is interactive via π-π stacking.

### Claim 55 (depends on 54)

The formulation of claim 54 wherein the at least a first group interactive via π-π stacking comprises an aromatic group.

### Claim 56 (depends on 55)

The formulation of claim 55 wherein the at least a first group interactive via π-π stacking comprises a benzyl group.

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60 (depends on 33)

The formulation of claim 33 wherein the at least one group comprising a plurality of hydroxyl groups is a hydrophilic group.

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69 (depends on 70)

The formulation of claim 70 wherein the nucleoside is selected from the group consisting of a gemcitabine, azacytidine, cytarabine or a biologically active derivative thereof.

### Claim 70 (depends on 71)

The formulation of claim 71 wherein the therapeutic agent is a nucleoside.

### Claim 71 (depends on 33)

The formulation of claim 33 wherein the at least one group comprising a plurality of hydroxyl groups is a therapeutic agent or a diagnostic agent and is covalently attached to a first linking group, which is interactive via π-π stacking, via a linking moiety that is labile in vivo.

### Claim 72

(canceled)

### Claim 73

(canceled)

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78 (depends on 71)

The formulation of claim 71 wherein the nanocarriers are micelles having a diameter no greater than 50 nm.

### Claim 79

(canceled)

### Claim 80

(canceled)

### Claim 81

(canceled)

### Claim 82

(canceled)

### Claim 83 (depends on 78)

The formulation of claim 78 wherein the micelles have a loading capacity for the first compound of at least 4-30% by weight.

### Claim 84

(canceled)

### Claim 85

(canceled)

### Claim 86

(canceled)

### Claim 87

(canceled)

### Claim 88

A method of formulating a composition for delivery of a first compound, which is a hydrophobic therapeutic compound or a hydrophobic diagnostic compound, comprising: mixing a plurality of polymers comprising a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one group including a plurality of hydroxyl groups, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one hydrophilic polymer with a plurality of the first compounds, wherein at least one of the first plurality of pendant groups or the second plurality of pendant groups is attached to the hydrophobic polymer backbone via a linking moiety comprising at least one group which is interactive via π-π stacking, and wherein the plurality of polymers self-assemble into nanocarriers in an aqueous environment into which the first compound is loaded.

### Claim 89

(canceled)

### Claim 90

(canceled)

### Claim 91

(canceled)

### Claim 92

(canceled)

### Claim 93

(canceled)
